Keyword: UnitedHealth Group
Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year.
In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.
UnitedHealthcare is planning to offer rebates directly back to millions of patients—a move that addresses a top criticism from the drug industry.
California Gov. Jerry Brown signed a new regulation limiting copay couponing, dealing a second key loss for the industry in the state.
Will Amazon shake up pharma just as it's upturning the grocery business? Industry watchers are scrying a steady drip-drip-drip of leaking info.
Readers are full of surprises. Sometimes, stories we editors put on top of the news don’t make the cut with readers. Others are unexpected hits. Still others resurface from the past. Find all three in this year's roundup of 2016 news curated by you, our readers.
Dealing a blow to Sarepta Therapeutics’ launch efforts, leading U.S. insurer Anthem has decided not to cover the pricey duchenne muscular dystrophy drug Exondys 51.
UnitedHealth dropped the latest formulary bomb Wednesday with a proposal to exclude Sanofi’s insulin Lantus and Amgen’s infection-fighter Neupogen in favor of their biosimilars. The insurer, among the top three in the U.S., also kicked off Novartis’ leukemia drug Gleevec, replacing it with Sun Pharma's generic.